MedTrace Logo

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

NCT02226146 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-11-26

Study results available
· View outcomes & findings →

Summary

This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.

Conditions

  • Pemphigoid, Bullous

Interventions

BIOLOGICAL

Bertilimumab

Sponsors & Collaborators

  • Immune Pharmaceuticals

    collaborator INDUSTRY

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226146 on ClinicalTrials.gov